Royal Bank of Canada
XRTX

Royal Bank of Canada’s XORTX Therapeutics XRTX Stock Holding History

Royal Bank of Canada’s Portfolio XRTX Stock Details XRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-818
Closed -$2K – 7755
2025
Q4 		$2K Buy
818
+746
+1,036% +$2.47K ﹤0.01% 6933
2025
Q3 		$0 Sell
72
-61
-46% -$256 ﹤0.01% 7582
2025
Q2 		$1K Buy
+133
New +$628 ﹤0.01% 6946
2025
Q1 		– Sell
-299
Closed -$2K – 7293
2024
Q4 		$2K Buy
299
+165
+123% +$1.14K ﹤0.01% 6737
2024
Q3 		$1K Sell
134
-111
-45% -$950 ﹤0.01% 6754
2024
Q2 		$2K Buy
+245
New +$3.28K ﹤0.01% 6758
2024
Q1 		– Sell
-105
Closed -$1K – 7683
2023
Q4 		$1K Buy
105
+104
+10,400% +$7.67K ﹤0.01% 7003
2023
Q3 		$0 Buy
+1
New +$261 ﹤0.01% 7677
2023
Q2 		– Hold
0
– – – 7713
2023
Q1 		– Sell
-1
Closed -$251 – 7558
2022
Q4 		$0 Buy
+1
New +$355 ﹤0.01% 7795
2022
Q3 		– Sell
-2
Closed -$1.13K – 7938
2022
Q2 		$1K Sell
2
-2
-50% -$1.27K ﹤0.01% 7227
2022
Q1 		$3K Buy
4
+3
+300% +$1.98K ﹤0.01% 7412
2021
Q4 		$1K Buy
+1
New +$1.03K ﹤0.01% 7550

Other funds holding XRTX

KWM
Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.9B AUM 18.41% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Royal Bank of Canada's XRTX Position: Q1 2026 in Review

Royal Bank of Canada sold out of XORTX Therapeutics (XRTX) in Q1 2026, closing a stake of 818 shares — an estimated $2K sold.

Royal Bank of Canada first reported a position in XRTX in Q4 2021 and held it in 12 quarters. The position peaked at $3K in Q1 2022. 3 funds tracked by Wall St. Rank hold XRTX as of Q1 2026.

  • Royal Bank of Canada reported no remaining XORTX Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 818 XORTX Therapeutics shares in Q1 2026, an estimated $2K.
  • Royal Bank of Canada first reported a position in XORTX Therapeutics in Q4 2021 and held it in 12 quarters.
  • Royal Bank of Canada's XORTX Therapeutics position peaked at $3K in Q1 2022.
  • 3 funds tracked by Wall St. Rank held XORTX Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.